Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial

Annals of Internal Medicine

Volumn 150, Issue 1, 2009, Pages 9-18

  Dore, David D ^a   Lapane, Kate L ^b   Trivedi, Amal N ^b   Mor, Vincent ^b   Weinstock, Martin A ^c  

^a i3 Drug Safety   (United States)

^b BROWN UNIVERSITY   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; RETINOIC ACID; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DERMATOLOGIST; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; EAR; FACE; FEMALE; FOLLOW UP; HUMAN; KERATINOCYTE; KERATINOCYTE CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACY; PHYSICAL EXAMINATION; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN CARCINOMA; VETERAN;

EID: 58149377900     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-1-200901060-00004     Document Type: Article

References (57)

1. American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Soc; 2006.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30:774-8. [PMID: 8176018]
3. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Arch Dermatol. 1993;129:1286-90. [PMID: 8215493]
4. Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol. 2007;127:2323-7. [PMID: 17522705]
5. Weinstock MA, Bogaars HA, Ashley M, Litle V, Bilodeau E, Kimmel S. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol. 1991;127:1194-7. [PMID: 1863078]
6. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354:723-9. [PMID: 10475183]
7. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. [PMID: 16899775]
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. [PMID: 9613910]
9. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. [PMID: 15755765]
10. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-9. [PMID: 15110204]
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45. [PMID: 16287954]
12. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23:726-30. [PMID: 12820814]
13. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23:194-201. [PMID: 17259710]
14. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-52. [PMID: 14744837]
15. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211-6. [PMID: 10866868]
16. Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol. 2004;3:369-71. [PMID: 15157852]
17. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607-8. [PMID: 15145635]
18. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643-7. [PMID: 15578694]
19. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-92. [PMID: 15917383]
20. Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5:579-94. [PMID: 16375664]
21. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11:306-15. [PMID: 16549815]
22. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88-94. [PMID: 18199714]
23. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol. 2008;103:825-37. [PMID: 18371146]
24. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18:213-9. [PMID: 17235211]
25. Blais L, Desgagné A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363-8. [PMID: 10927735]
26. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302-9. [PMID: 18374689]
27. Jagdeo J, Weinstock MA, Piepkorn M, Bingham SF.Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Reliability of the histopathologic diagnosis of keratinocyte carcinomas. J Am Acad Dermatol. 2007;57:279-84. [PMID: 17482716]
28. Weinstock MA, Bingham SF, Cole GW, Eilers D, Naylor MF, Kalivas J, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137:1055-8. [PMID: 11493098]
29. Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rev. 2003;60:92S-123S. [PMID: 15095548]
30. Gallagher RP, Hill GB, Bajdik CD, Coldman AJ, Fincham S, McLean DI, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol. 1995;131:164-9. [PMID: 7857112]
31. Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int J Cancer. 1995;60:489-94. [PMID: 7829262]
32. Lear JT, Tan BB, Smith AG, Bowers W, Jones PW, Heagerty AH, et al. Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med. 1997;90:371-4. [PMID: 9290417]
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83. [PMID: 3558716]
34. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-9; discussion 1081-90. [PMID: 8410092]
35. Fortina AB, Piaserico S, Caforio AL, Abeni D, Alaibac M, Angelini A, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol. 2004;140:1079-85. [PMID: 15381547]
36. Grau MV, Baron JA, Langholz B, Karagas M, Greenberg ER, Stukel TA, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer. 2006;119:682-6. [PMID: 16496410]
37. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14:465-76. [PMID: 15651087]
38. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-56. [PMID: 16624967]
39. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the 26th Annual SAS Users Group International Conference, Long Beach, California, 22-25 April 2001. Cary, NC: SAS Institute; 2001:214-26.
40. Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006;60:1028-34. [PMID: 16939542]
41. Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev. 2005:CD003697. [PMID: 16235336]
42. Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control. 2008;19:767-74. [PMID: 18322813]
43. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:2218-25. [PMID: 17971519]
44. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2007;16:2226-32. [PMID: 18006910]
45. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98:1819-25. [PMID: 17179483]
46. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007;99:32-40. [PMID: 17202111]
47. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133:393-402. [PMID: 17681160]
48. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134-9. [PMID: 18182618]
49. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500, 000 veterans. Urology. 2008;71:118-22. [PMID: 18242378]
50. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27-33. [PMID: 17179016]
51. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80. [PMID: 16391219]
52. Salinas CA, Agalliu I, Stanford JL, Lin DW. Statins and the risk of cancer [Letter]. JAMA. 2006;295:2721; author reply 2721-2. [PMID: 16788124]
53. Freeman MR, Solomon KR, Moyad M. Statins and the risk of cancer [Letter]. JAMA. 2006;295:2720-1; author reply 2721-2. [PMID: 16788122]
54. Salinas CA, Agalliu I, Stanford JL, Lin DW. Statins and the risk of cancer [Letter]. JAMA. 2006;295:2721; author reply 2721-2. [PMID: 16788124]
55. Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41:761-74. [PMID: 12773842]
56. Karagas M, Weinstock M, Nelson H. Keratinocyte carcinomas (basal and squamous cell carcinomas of the skin). In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford Univ Pr; 2006:1230-50.
57. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006;98:923-8. [PMID: 16996875]